Optimizing Auvelity Prior Authorization for Gastroenterology Practices

The Intersection of Auvelity and Gastroenterology Practice

While Auvelity is not a primary GI medication, gastroenterologists frequently manage patients with comorbid depression or anxiety, particularly those with chronic conditions like Inflammatory Bowel Disease (IBD) or Irritable Bowel Syndrome (IBS). Prescribing Auvelity in this context means GI practices must navigate its prior authorization requirements, adding to an already high-volume PA workload. Klivira understands this integrated care approach and the resulting administrative demands.

Typical Documentation for Auvelity Prior Authorization

• Confirmed diagnosis of Major Depressive Disorder (MDD) or other approved indication.
• Documentation of prior antidepressant trials and their efficacy or intolerance.
• Assessment of symptom severity and functional impairment.
• Confirmation of no contraindications (e.g., MAOI use, seizure disorder).
• Payer-specific step therapy adherence, if applicable.

Navigating the Broader Prior Authorization Landscape in Gastroenterology

Beyond medications for comorbid conditions, gastroenterology stands out for its extensive prior authorization requirements. High-volume categories include IBD biologics (e.g., Humira, Stelara, Skyrizi, Entyvio), specialty drugs for functional GI disorders (e.g., Viberzi, Motegrity, Linzess), advanced imaging (MRCP, CT enterography), and specific endoscopic procedures like capsule endoscopy or ERCP. This constant stream of diverse PA requests highlights the need for robust automation.

Common Denial Reasons for Auvelity and Other GI Medications

• Failure to meet payer-specific step therapy requirements (e.g., inadequate trial of alternative agents for depression, or biosimilar substitution for biologics).
• Insufficient documentation of diagnosis criteria or disease severity (e.g., missing Rome criteria for IBS, or Mayo score for UC).
• Incomplete submission of supporting clinical notes or lab results (e.g., TB/hepatitis screening for biologics, genotype/fibrosis stage for Hep C DAAs).
• Lack of documented medical necessity or failure to adhere to clinical guidelines (e.g., ACG, AGA).
• Incorrect classification of treatment-naive vs. treatment-experienced status.

Klivira's Solution for Comprehensive Gastroenterology PA Management

Klivira's platform provides a holistic approach to prior authorization for gastroenterology practices, encompassing both specialty-specific GI treatments and medications like Auvelity. By integrating with EMRs and automating submissions via X12 278, ePA, and payer portals, Klivira reduces manual effort and accelerates approval times. Our system incorporates payer-specific policy logic, including ACG/AGA-guideline-aware step therapy and treatment-status classification, to proactively address common denial reasons.

Klivira's Benefits for Gastroenterology Prior Authorization

• Automated submission across diverse channels (X12, ePA, payer portals).
• EMR integration for seamless data extraction (e.g., medication history, diagnostic results).
• Real-time tracking and status updates for all PA requests.
• Proactive identification of documentation gaps based on payer rules.
• Support for periodic re-authorization workflows for chronic treatments.
• Intelligent routing for medical vs. pharmacy benefit distinctions.